Gene Therapy for Sickle Cell Disease Shows Promising Safety and Efficacy in 36 Patients
An expanded access protocol for a gene therapy targeting BCL11A in sickle cell disease has shown increased fetal hemoglobin levels without unexpected safety issues in 36 patients.